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Abstract: Boronic acid transition-state analog inhibitors (BATSIs) are partnerswith -lactamantibiotics
for the treatment of complex bacterial infections. Herein, microbiological, biochemical, and structural
findings on four BATSIs with the FOX-4 cephamycinase, a class C  -lactamase that rapidly hydrolyzes
cefoxitin, are revealed. FOX-4 is an extended-spectrum class C cephalosporinase that demonstrates
conformational flexibility when complexed with certain ligands. Like other  -lactamases of this
class, studies on FOX-4 reveal important insights into structure–activity relationships. We show that
SM23, a BATSI, shows both remarkable flexibility and a nity, binding similarly to other  -lactamases,
yet retaining an IC50 value < 0.1 µM. Our analyses open up new opportunities for the design of novel
transition-state analogs of class C enzymes.
Keywords:  -lactam;  -lactamase; cephamycinase; boronic acid; transition-state analog inhibitor
1. Introduction
 -lactam resistance continues to increase, threatening public health worldwide. Of particular
concern are carbapenem-resistant Enterobacteriaceae (CRE) that have evolved to inactivate our
“last-line” therapy [1]. Dual-target strategies, in which one drug is a  -lactamase inhibitor (BLI)
while a second drug (a  -lactam) inhibits the cell wall-building machinery, are increasingly used to
treat infections caused by  -lactam-resistant bacteria [2]. This approach increases the usefulness of
antibiotics that are otherwise susceptible to hydrolysis by  -lactamases.
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Boronic acid transition-state analog inhibitors (BATSIs) have emerged as promising non- -lactam
BLIs that can inhibit all four structural classes of  -lactamase [3]. In combination with existing
 -lactams, BATSIs have increased the potency and e cacy of other antibiotics and were shown to have
in vivo activity [4]. The first generation of BATSIs inactivated serine  -lactamases (Ambler classes A,
C, and D) through a dative and reversible covalent bond to the active site serine nucleophile [5–8].
Many of these compounds contained side chains that mimicked known cephalopsorins, such as those
considered in this study (Figure 1). Medicinal chemistry e↵orts have refined many additional side
chains to great e↵ect [9,10], including some that inhibit both serine- and metallo- -lactamases (Ambler
class B) [11]. The recent development of cyclic BATSIs, in which the substituent binds twice to the boron,
has added increased potency and range to this group of BLIs [12–14]. Vaborbactam, a monocyclic
BATSI, recently received fast-track status by the Food and Drug Administration as a BLI to be used
in combination with an existing  -lactam, meropenem [15–17]. Vaborbactam only binds strongly
to class A and C  -lactamases; several bicyclic boronates currently in development have broader
inhibition profiles. A bicyclic BATSI, QPX7728, was recently reported to bind 4- to 10,000-fold more
tightly to serine  -lactamases and also to metallo- -lactamases with submicromolar a nity [18,19].
Taniborbactam (VNRX-5133), another bicyclic BATSI, inhibits all classes of  -lactamases and shows
particularly high a nity to VIM family metallo- -lactamases [20].Biomolecules 2020, 10, x FOR PEER REVIEW 3 of 15 
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Figure 1. Compounds used in this study. R1 and R2 indicate side chains that are analogous to those of
 -lactam substrates. Dashed lines indicate the portion of LP06 that is missing in the electron density of
the FOX-4/LP06 crystal structure (PDB: 5CHM). * An extra carbon linker is present on the R2 side chain.
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Inhibition strategies are especially relevant for class C enzymes, which are considered resistant
to inhibition by three of the six approved BLIs (the recently approved avibactam, relebactam,
and vaborbactam are the exceptions, for now). Structural studies show that BATSI binding mimics
many aspects of the  -lactam interactions with AmpC [5,21]. As a result, BATSIs can also be used as
structural probes of these  -lactamases. BATSI-bound crystal structures for class A  -lactamases are
well established, including several CTX-M family members [10], TEM-1, SHV-1, and (importantly)
KPC-2 [22–24]. Class C enzymes have not received the same attention—most structures arewith a single
enzyme, Escherichia coli AmpC [6,9,25–27], although three recent analyses describing ADC-7/BATSI
and PDC/BATSI complexes have expanded this repertoire considerably [14,28,29]. Other structures
include Enterobacter cloacae P99 and 908R.
The FOX-4 cephalosporinase–BATSI structures presented herein add a cephamycinase to this
growing list. Plasmid-based extended-spectrum AmpC enzymes, such as the FOX  -lactamases,
are increasingly found in clinical isolates from antibiotic-resistant infections [30,31]. FOX-4 is of interest
because it rapidly hydrolyzes cephamycins [32]. These compounds contain a 7↵-methoxy substituent on
the cephem ring that mimics the 6↵-(2)-hydroxyethyl group characteristic of carbapenems (imipenem),
raising the concern that cephamycinases may evolve to hydrolyze carbapenems [33]. In addition,
the FOX-4  -lactamase shows significant ligand-induced conformational changes in the R2 loop and
H10 helix.
SM23, a chiral cephalothin (CEF)-based BATSI, bears an R1 side chain with a thiophene ring and
an R2 side chain with a m-carboxyphenyl functionality (Figure 1). This designed compound is among
the most potent BATSIs, inhibiting class C  -lactamases with < 0.1 µM IC50 values [6]. In PDC-3,
this compound is an e↵ective inhibitor, as are a series of novel BATSI compounds [34].
In this analysis, the structure of FOX-4 in complex with SM23 and LP06, a ceftazidime mimic,
is described. These structures reveal similar binding modes across distantly related class C enzymes
such as ADC-7, PDC-3 and E. coli AmpC, and suggest a common mode of action. The recent
ADC-7 and PDC-3 structures are now joined by the FOX-4 structures as representatives of class C
 -lactamases bound to transition-state analogues. Herein, we describe these structures and compare
the conformations of the inhibitors bound to FOX-4 and E. coli AmpC to each other and that of
a cephamycin, cefoxitin.
2. Materials and Methods
Reagents and compounds. Lysogeny broth (LB) powder was purchased from ThermoFisher
Scientific (Springfield, NJ, USA). Nitrocefin (NCF) was obtained from TOKU-E (Bellingham, WA, USA).
Unless otherwise specified, all chemicals were from Sigma-Aldrich (St. Louis, MO, USA) and were of
the highest grade available.
Minimum Inhibitory Concentrations (MICs). An E. coli 42015 clinical strain producing blaFOX-4
and E. coli TG1 carrying pBGS18  blaFOX-4 were subjected to susceptibility testing; these strains were
previously described [32,35]. MICs were determined using cation-adjusted Mueller–Hinton (MH)
broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) guidelines [36].
The ceftazidime (CAZ) concentration was varied, while a constant concentration of 10 µg/mL of the
BATSI compounds was used.
Protein expression and purification. Native FOX-4 was produced as previously described [33].
Briefly, periplasmic fractions of E. coli expressing FOX-4 from a clinically derived plasmid were
incubated with a m-aminophenylboronic acid resin equilibrated in a bu↵er containing 25 mM Tris
pH 7.0 and 500 mM sodium chloride; the resin (3 mL) was transferred to a column (1 cm diameter)
and the flow through was collected; the column was washed with 10 volumes of equilibration bu↵er
(0.3 mL/min) and eluted with a bu↵er containing 500 mM sodium borate pH 7.0 and 500 mM sodium
chloride. Fractions of 95% purity were dialyzed for kinetics (50 mM Tris pH 7.5) and concentrated
for crystallization.
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Steady-state kinetics. Steady-state kinetics were carried out on a Cary300 (Agilent, Palo Alto,
CA, USA) UV–VIS spectrophotometer as described previously [34]. Briefly, the reporter substrate,
NCF, and inhibitors were dissolved in 10 mM phosphate-bu↵ered saline pH 7.4 (PBS).  -lactamase
stocks were diluted into PBS containing 0.1 mg/mL bovine serum albumin (ThermoFisher Scientific,
Waltham, MA, USA) to improve stability. Velocity vs. substrate concentration data were fit to the
Henri–Michaelis–Menten equation (Equation (1)) [37]:
v = Vmax[S]/(Km + [S]) (1)
using Kaleidagraph version 4.5 (Synergy Software, Reading, PA, USA).
Experimental evidence so far suggests that BATSIs bind to  -lactamases according to the following
mechanism (Equation (2)) [38]:
E + I⌦ E:I⌦ E-I* (2)
where E:I represents a reversible binding complex and E-I* represents the covalent, reversible complex
mimicking the transition state of either the acylation or deacylation reaction of a  -lactam substrate.
The concentration of inhibitor required to reduce FOX-4’s activity by 50% (IC50) was determined
using NCF (140 uM) as the reporter substrate, and represents the concentration of inhibitor that gives
50% of the initial velocity. The parameter was estimated from the y-intercept of the linear plot of
reciprocal initial velocity versus inhibitor concentration (Equation (3)) [34]:
1/v0 = Km/(Vmax[S]) ⇥ (1 + [I]/IC50) + 1/Vmax. (3)
BATSIs were pre-incubated with FOX-4 for 5 min before addition of NCF. The IC50 values were
adjusted for the use of NCF as previously described [29].
X-ray crystallography. Di↵raction quality crystals for FOX-4 were grown by sitting drop vapor
di↵usion bymixing 1 µL of protein (15mg/mL in 50mMTris:HCl, pH 7.5) with 1 µL of reservoir solution
and equilibrating the samples against the corresponding reservoir solution. The reservoir solution
contained 0.05 M zinc acetate and 20% PEG 3350. Crystals with dimensions 0.1 ⇥ 0.1 ⇥ 0.2 mm3
were mounted in cryo-loops directly from the crystallization droplet and flash cooled in liquid
nitrogen. Prior to freezing, 20% glycerol was added to the drop as a cryo-protectant. Both soaking
in the drop and co-crystallization were used to obtain structures of the complexes with inhibitors.
Di↵raction data were recorded on a Rayonix 225 HE CCD detector (Ryonyx, L.L.C., Evanston,
IL, USA) with 0.979 Å wavelength radiation on the LRL-CAT beamline (Advanced Photon Source,
Argonne, IL, USA). Intensities were integrated using the HKL2000 program and reduced to amplitudes
using the SCALEPACK2MTZ program (see Table 1 for statistics) [39,40]. All structures were solved
using molecular replacement with PHASER [41] and a PDB 1ZKJ structure as a starting model.
Final model building and refinement was performedwith the programs COOT, REFMAC, and PHENIX,
respectively [42–44]. The quality of the final structures was verified with composite omit maps,
and stereochemistry was checked with the programMOLPROBITY [45]. LSQKAB and SSM algorithms
were used for structural superpositions [46,47]. All other calculations were conducted using the CCP4
program suite [39]. Structures were deposited in the Protein Data Bank (PDB) as 5CHJ (FOX-4/SM23)
and 5CHM (FOX-4/LP06).
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Table 1. Data collection and refinement statistics for the FOX-4 crystal structures.
WT WT
Ligand SM23 cephalothin (CEF) analog LP06 ceftazidime (CAZ) analog
PDB entry 5CHJ 5CHM
Data Collection
Resolution range (Å) 20.0–1.4 20.0–1.9
Wavelength (Å) 0.979 0.979
Space group P21 P21
Unit cell dimensions (Å)
a = 74.29 a = 54.85
b = 57.16 b = 57.09
c = 83.23 c = 56.75
↵ =   = 90  ↵ =   = 90 
  = 91.67    = 96.45 
Observed reflections 539,219 94,986
Unique reflections 147,034 27,189
Completeness (%) a 97.8 (96.5) 98.8 (98.0)
I/  9.9 (2.6) 7.6 (2.8)
Rmerge (I) b 0.067 (0.448) 0.094 (0.422)
Structure Refinement
Rcryst (%) c 0.163 0.170
Rfree (%) c 0.192 0.228
Protein non-hydrogen atoms 5511 2722
Water molecules 1009 237
Average B-factor (Å2) 9.5 15.6
RMS Deviations from Ideal Value
Bonds (Å) 0.011 0.007
Angles ( ) 1.46 1.09
Torsion angles ( ) 13.5 13.5
Overall coordinate error
(Maximum likelihood) 0.11 0.22
Ramachandran Statistics (%)
(For non-Gly/Pro residues)
Most favorable 98.1 97.8
Additional allowed 1.9 2.2
a Values in parentheses indicate statistics for the high-resolution bin. b Rmerge = SS j |Ij(hkl)   <I(hkl)>|/SS j |<I(hkl)>|,
where Ij is the intensity measurement for reflection j and <I> is the mean intensity over j reflections. c Rcryst/(Rfree) =
S ||Fo(hkl)   |Fc(hkl)||/S |Fo(hkl)|, where Fo and Fc are observed and calculated structure factors, respectively. In total,
5% of the reflections were excluded from refinement and used to calculate Rfree.
Structure Visualization. Protein and ligand superpositions were made using the align function
in PyMol (Schrödinger) using all atoms of the complexes being compared. Omit maps revealing
high quality density consistent with the inhibitors were calculated as described below. The final
coordinates (5CHM and 5CHJ) were modified with PDBSET (CCP4) by removal of the ligand atoms,
uniform adjustment of all B-factors to 20, and adjustment of atomic positions of all remaining atoms by
application of random shifts of up to 0.2 Å. The resulting files were subjected to standard refinement
with Refmac5 (CCP4) for 40 cycles with tight geometric restraints. Di↵erence maps (2mFo-DFc and
mFo-DFc) were calculated with FFT (CCP4) and contoured with MAPMASK (CCP4) around the
polypeptide coordinates.
3. Results
Combining CAZ with a BATSI lowers the CAZ MICs for E. coli carrying blaFOX-4. To assess the
potency of the inhibitors in whole cells, broth microdilution MIC testing was performed (Table 2).
When chiral m-carboxyphenyl cephalothin (CEF) analog (SM23) was paired with the  -lactam CAZ,
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the MIC for CAZ decreased from  128 to 4 µg/mL for E. coli TG1 pBGS18  blaFOX-4 (to 32 µg/mL for
E. coli 42015 blaFOX-4). The extra carbon linker present on the cephalothin (CEF*) analog (EC04) resulted
in decreased potency of CAZ. The cefotaxime analog (CTX-like) compound decreases the MIC values
from 128 to 16 µg/mL for E. coli TG1 pBGS18  blaFOX-4.










E. coli blaFOX-4 >128 32 64 64 16
E. coli TG1 pBGS18-blaFOX-4 128 4 16 16 1
# Concentrations of ceftazidime (CAZ) are in µg/mL; BATSI is present at a constant concentration of 10 µg/mL;
the CLSI breakpoint for CAZ resistance is an MIC   16 µg/mL. Cephalothin (CEF); cefotaxime (CTX). * An extra
carbon linker is present on the R2 side chain.
The extra carboxyl group present on the CAZ analog (LP06) may be beneficial for cell penetration,
as the MIC values decreased significantly from 128 to 1 µg/mL for E. coli TG1 pBGS18  blaFOX-4.
In addition, the CAZ–LP06 MIC values for the clinical E. coli 42015 blaFOX-4 strain were the lowest
(16 µg/mL) of the group of CAZ–BATSI combinations tested.
BATSIs are potent inhibitors of the FOX-4 cephamycinase. FOX-4 was probed with four BATSIs
(Figure 1) to determine IC50 values (Table 3). BATSIs bind tightly to FOX-4 and show the same trend in
binding a nity as for AmpC (E. coli) and PDC-3 (Pseudomonas-derived cephalosporinase). The tightest
FOX-4-binding compound, SM23 (CEF analog), has a IC50 that is 3-fold lower than LP06 (CAZ analog),
running counter to the MIC result: LP06 reduces the CAZMIC two logs more than SM23. In agreement
with the MIC data, however, the EC04 (CEF* analog) binds an order of magnitude less well than
SM23 (CEF analog). LP06 (CAZ analog) mimics the CTX-like BATSI, and binds 2.5-fold more tightly,
suggesting that the extended oxime side chain encourages binding.








SM23 (CEF-like) 0.032 ± 0.003 0.001 0.004
EC04 (CEF *-like) 0.42 ± 0.02 n.d. 0.22
CTX-like 0.26 ± 0.02 0.31 4 0.17
LP06 (CAZ-like) 0.11 ± 0.02 0.020 4 0.004
1 This study. 2 Ref [6,21]. 3 Ref [34]. 4 No time-dependent inhibition was observed, so these values represent true
Ki values. Cephalothin (CEF); cefotaxime (CTX); ceftazidime (CAZ). * An extra carbon linker is present on the R2
side chain.
Complex of FOX-4 with SM23. Both crystal soaking and co-crystallization were employed to
reveal the structure of the complex. Initially, a stock solution of SM23 (CEF analog) in DMSOwas added
directly to the crystallization drops containing crystals. However, DMSO damaged the crystals in
a time- and concentration-specific manner. The best result was obtained by soaking crystals for 15 min
in the 4 µL drop after addition of 0.1 µL 250 mM SM23 (CEF analog) in DMSO. The crystal di↵racted to
1.2 Å, with only partial inhibitor occupancy. Alternatively, FOX-4 was incubated with 2 mM SM23 (CEF
analog) and then crystallized. Both structures are virtually identical, but co-crystallization achieves
full occupancy and this structure was deposited in the PDB (5CHJ).
SM23 (CEF analog) binding results in larger unit cell (Table 1). While apo enzyme crystals contain
one FOX-4 chain per asymmetric unit [33], SM23 (CEF analog) complex crystals contain two chains per
asymmetric unit with an RMSD of 0.27 (0.52) Å between C↵ (all) atoms. The largest di↵erence occurs
in the loop near T213, just out of contact with the inhibitor.
The boron covalently binds to S64 (Figure 2A). The two boronate oxygens adopt positions
consistent with all prior BATSI structures in class C enzymes; one oxygen points into the oxyanion
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hole and the other takes the presumed position of the deacylating water [21]. The carboxyphenyl
ring of SM23 (CEF analog) binds in the canonical binding site of cephalosporins, via hydrogen bonds
between the carboxylate, S318, and N343 that are mediated by water molecules (Figure 2B). The BATSI
carboxyphenyl ring appears to form parallel-displaced ⇡-stacking interactions with the side chain
of F293, a residue that is unique to the FOX family. We note that the repositioning of L119 seems
to be in response to the large conformational change of F293 between the apo and liganded forms.
Additionally, the thiophene ring extends out of the active site and does not make significant contacts;
instead, it veers away from the Y221 side chain. By comparison, the E. coli AmpC-SM23 (CEF analog)
structure (1MXO) has the thiophene ring 1.9 Å closer to Y221 (Figure 2D). The thiophene conformations
of SM23 (CEF analog) are unlike the cognate structures of CEF and cefoxitin in complex with the E. coli
AmpC, where parallel ⇡-stacking interactions are evident.
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Overall, the SM23 (CEF analog) adopts a similar shape in both FOX-4 and the E. coli AmpC,
with the positioning di↵erences apparently linked to the side chain conformation of L119 and the steric
bulk of F293 versus L293 (Figure 2C,D). Notably, the amide carbonyls in both structures point toward
N152 in spite of these side chain di↵erences, suggesting a common requirement for binding.
Cefoxitin contains the same R1 side chain as SM23 (CEF analog), and FOX-4 uses the same active
site elements to bind both molecules. However, a structure of FOX-4 Y150F (deacylation-impaired)
acylated with cefoxitin shows that the dihydrothiazine ring of cefoxitin is rotated 100  relative to the
carboxyphenyl ring of SM23 (CEF analog), positioning the C4-carboxylate within hydrogen-bonding
distance of Q120 (Figure 2E). The ring orientation of cefoxitin may be associated with formation of
a product-like conformation that speeds its deacylation. Since the carboxylate of the carboxyphenyl
ring of SM23 (CEF analog) binds in the canonical region consisting of S318, N343, and R349 in
FOX-4, this interaction may be the most significant one for increasing binding a nity. All crystal
structures of bound BATSIs with a carboxyphenyl ring (i.e., SM23 (CEF analog) and EC04 (CEF* analog))
show the same conformation of this group, though the precise residues involved vary across class C
 -lactamases [48,49]. It may be that the direct hydrogen bond to Q120 seen in the FOX-4 Y150F/cefoxitin
(PDB: 5CGX) and E. coli AmpC N152G/cefoxitin (PDB: 4KEN) structures is either conformationally
unfavorable for the BATSI carboxylate, or that the canonical site is that much more appealing.
Complex of FOX-4 with LP06 (CAZ analog). Both crystal soaking and co-crystallization were
employed to reveal the structure of the complex of FOX-4 with LP06 (CAZ analog). LP06 has the R1
side chain of CAZ and aztreonam. Firstly, LP06 (CAZ analog) solution in DMSO was added to the
crystallization drop to bring the inhibitor concentration to 9 mM, and the crystal was frozen after 2 h.
The electron density map at a resolution of 1.9 Å shows the LP06 (CAZ analog) molecule covalently
attached to S64, but the oxyimino side chain, past the imine nitrogen, is missing. This structure was
deposited in the PDB (5CHM).
For co-crystallization, protein was incubated with 5 mM LP06 (CAZ analog) and then crystallized.
The structure was solved at a resolution of 1.7 Å. In contrast to the SM23 (CEF analog) complex in
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which inhibitor binding caused change in the unit cell parameters, the LP06 (CAZ analog) complex has
the same unit cell as apo FOX-4. Electron density in the co-crystallized structure was more di cult to
interpret: just like the soaked complex, the oxime side chain is missing, and the aminothiazole ring has
two poses that di↵er from the soaked complex. This structure was not considered further.
The visible portions of LP06 (CAZ analog) bound to FOX-4 (PDB: 5CHM) strongly resemble LP06
bound to E. coli AmpC (PDB: 1IEM), and are consistent with CAZ in the acyl-enzyme of E. coli AmpC
(PDB: 1IEL) (Figure 3). The side chain of LP06 (CAZ analog) has been modeled (ball and stick), for
reference from the E. coli AmpC-LP06 structure. In these three structures, in contrast to SM23 (CEF
analog), the R1 ring of LP06 (CAZ analog) (aminothiazole) makes edge-to-face ⇡-stacking interactions
with the side chain of Y221. The somewhat more extended chain still retains the amide carbonyl
hydrogen bond to N152. The bulky oxime group, which is missing in the FOX-4 structure, is well
resolved in the E. coli AmpC structures with the carboxylate oriented toward its canonical carboxylate
binding pocket (N343, R349). The W loop may participate in binding of this carboxylate through
an extended hydrogen-bonded network including K203.
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Figure 3. Comparison of BATSIs binding to F -4. (A,B) Omit maps of the ligand electron density
were contoured at 3.0 R.M.S.D. for SM23 (CEF analog) and LP06 (CAZ analog) (A and B, respectively).
(C)Overlayof theFOX-4/SM23 complex (yellow/violet) andFOX-4/LP06 complex (cyan/green) structures.
The BATSIs adopt very di↵erent conformations. The aminothiazole ring of LP06 forms edge-to-face
⇡-stacking interactions with Y221, while the thiophene ring of SM23 points away. The amide carbonyls
both form hydrogen bonds with N152. The missing electron density for LP06 is modeled by the
structure from E. coli AmpC (PDB: 1IEM). L119 moves away in the SM23 structure.
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4. Discussion
BATSIs are a class of promising transition-state analog inhibitors that have advanced toward
clinical use. Key to their continued development will be better structural analysis showing their
interactions with a wide range of targets. BATSI-bound crystal structures for class A  -lactamases
are well established, but class C enzymes do not yet enjoy the same attention—most structures are
with a single enzyme, E. coli AmpC. The BATSI-bound FOX-4 structures presented here, in addition to
the class C ADC-7 and PDC-3 structures, add a significant new understanding to this group of enzymes.
Lefurgy et al. determined the crystal structure of apo FOX-4 and the acyl-enzyme of cefoxitin
with the Y150F variant [33]. The cefoxitin-bound structures show only a few di↵erences in enzyme
conformation with the BATSI structures. When cefoxitin is bound, L119 adopts the canonical
conformation, the F293 side chain descends 4.0 Å further toward the active site, and the N152 side
chain is rotated away from the active site. The latter di↵erence seems to be the result of a repositioning
of the cefoxitin amide carbonyl by ~90 , relative to the BATSIs, placing it in hydrogen-bonding distance
to K67 and out of range of its usual binding partner, N152. These di↵erences are likely explained by
the steric hindrance between cefoxitin’s 7↵-methoxy group and N152 that results in a rearrangement
not seen in the BATSI conformation.
The R1 side chain rings adopt di↵erent conformations in FOX-4. In cefoxitin and LP06 (CAZ
analog), the ring is perpendicular with Y221 and makes side-to-face ⇡-stacking interactions; in SM23
(CEF analog), it moves out of range. It appears that the Y221 interaction is not predictive of binding
a nity overall.
Transition-state analogues such as SM23 (CEF analog) can give insight into the mechanism of
 -lactamase. As seen in the AmpC-CAZ/BATSI structures (PDB: 1IEL and 1IEM), the geometric
constraints on deacylation often require a conformational change by the acylating substrate that
is not always readily accommodated. In those structures, the position of the boronic oxygen that
represented the presumed deacylation water molecule was observed in the overlay to be too close
to the ring nitrogen of dihydrothiazine, suggesting that the substrate itself was occluding the water
from its required deacylation trajectory. So too, in the AmpC-moxalactam structure (PDB: 1FCO),
we see that the ring comes within 1.6 Å of the boronic oxygen, suggesting that this substrate also
prevents water from binding in a deacylation-competent position (Figure 4A). Making the same
comparison in FOX-4-cefoxitin/SM23 (CEF analog) structures (PDB: 5CGX and 5CHJ), we see that the
acyl-cefoxitin is able to adopt a ring conformation that places the sulfur 2.2 Å away from the boronic
oxygen, enough room (presumably) for a water molecule to make an attack trajectory (Figure 4B).
The repositioning of the ring into this conformation is possible because of a key bond rotation about
C7-C8 that is possible in the FOX-4 active site, but which appears to be sterically occluded in AmpC.
The structural di↵erences here are subtle and will require further analysis to fully understand, but may
include a slight widening of the active site due to replacement at position 153 of serine (AmpC) with
proline (FOX-4).
The enzyme a nity of the BATSIs is not necessarily a good predictor of their in vivo activity.
The IC50 values for SM23 (CEF analog) suggested that it would be more potent than LP06 (CAZ analog)
(0.032 µM vs. 0.11 µM), yet MIC values revealed that LP06 was in fact more potent than SM23 (1 vs. 4
µg/mL for the laboratory strain and and 16 vs. 32 µg/mL for the clinical strain)—perhaps owing to
increased penetration by LP06. The overall higher resistance of the clinical strain may be linked to
other resistance mechanisms, such as mutations in outer membrane proteins or the presence of drug
e✏ux pumps. The slightly reduced overall a nity of BATSIs for FOX-4, compared to E. coli AmpC
and PDC-3, may be rationalized by considering the replacements N346I and N289P, resulting in a
much sparser hydrogen-bonding network involving them-carboxyphenyl group (Figure 2C). The same
replacements may account for the disordered oxime side chain of LP06 (CAZ analog), which binds
in the same location. It is notable that the cefotaxime-like BATSI shows a slightly lower a nity than
LP06 (CAZ analog), suggesting that while the larger oxime side chain of LP06 is disordered, it does
contribute somewhat to the overall a nity.
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inhibitor that undergoes structural shifts in concert with its target enzyme (i.e., induced fit involving
changes in both ligand and protein) may be a paradigm for future inhibitor design. This observation
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but have a broader spectrum.
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